Drugs and the FDA: Safety, Efficacy, and the Public's Trust

★★★★★ 5.0 29 reviews

US$5.94
Price when purchased online
Free shipping Free 30-day returns

Sold and shipped by www.millry.net
We aim to show you accurate product information. Manufacturers, suppliers and others provide what you see here.
US$5.94
Price when purchased online
Free shipping Free 30-day returns

How do you want your item?
You get 30 days free! Choose a plan at checkout.
Shipping
Arrives Aug 2
Free
Pickup
Check nearby
Delivery
Not available

Sold and shipped by www.millry.net
Free 30-day returns Details

Product details

Management number 233416815 Release Date 2026/06/27 List Price US$5.94 Model Number 233416815
Category

How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer’s drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug’s safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA’s cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices. Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDA’s evolution, demonstrating how its system of checks and balances works—or doesn’t work. Read more

ISBN10 0262047314
ISBN13 978-0262047319
Language English
Publisher The MIT Press
Dimensions 6.38 x 1.06 x 9.25 inches
Item Weight 1.26 pounds
Print length 320 pages
Publication date September 27, 2022

Correction of product information

If you notice any omissions or errors in the product information on this page, please use the correction request form below.

Correction Request Form

Customer ratings & reviews

5 out of 5
★★★★★
29 ratings | 12 reviews
How item rating is calculated
View all reviews
5 stars
90% (26)
4 stars
0% (0)
3 stars
0% (0)
2 stars
0% (0)
1 star
10% (3)
Sort by

There are currently no written reviews for this product.